FDA Approves Avapritinib for Resectable or Metastatic Gastrointestinal Stromal Tumor

The FDA approved avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news